Back to top
more

Bicycle Therapeutics (BCYC)

(Real Time Quote from BATS)

$22.52 USD

22.52
139,926

-0.53 (-2.30%)

Updated Aug 13, 2024 03:44 PM ET

After-Market: $22.41 -0.11 (-0.49%) 4:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BCYC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 526 339 439 136 92
Receivables 24 21 12 15 7
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 11 9 8 5 5
Total Current Assets 562 369 459 156 104
Net Property & Equipment 15 19 3 2 2
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 6 8 3 2 2
Total Assets 595 411 480 161 110
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 13 6 3 1 2
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 32 26 14 12 6
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 25 20 19 10 1
Total Current Liabilities 70 53 36 23 9
Mortgages 0 0 0 0 0
Deferred Taxes/Income 110 41 52 25 5
Convertible Debt 0 0 0 0 0
Long-Term Debt 31 30 30 15 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 5 4 3 3 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 224 140 134 66 17
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 0 0 0 0
Capital Surplus 883 601 568 250 195
Retained Earnings -512 -331 -218 -152 -101
Other Equity -1 0 -3 -3 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 371 271 346 95 93
Total Liabilities & Shareholder's Equity 595 411 480 161 110
Total Common Equity 371 271 346 95 93
Shares Outstanding 30.00 29.60 29.40 17.70 17.70
Book Value Per Share 12.36 9.15 11.78 5.39 5.27

Fiscal Year End for Bicycle Therapeutics PLC Sponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 961 457 526 572 340
Receivables 47 39 24 17 58
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 20 20 11 14 10
Total Current Assets 1,028 516 562 603 408
Net Property & Equipment 12 13 15 16 18
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 7 6 6 5 12
Total Assets 1,057 547 595 639 454
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 7 7 13 8 5
Current Portion Long-Term Debt 22 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 28 26 32 34 37
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 12 16 25 27 30
Total Current Liabilities 70 50 70 70 72
Mortgages 0 0 0 0 0
Deferred Taxes/Income 94 98 110 108 115
Convertible Debt 0 0 0 0 0
Long-Term Debt 9 31 31 31 31
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 5 5 4 4
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 184 191 224 223 234
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 1,452 895 883 875 633
Retained Earnings -578 -538 -512 -463 -413
Other Equity -1 -1 -1 3 -1
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 874 356 371 416 220
Total Liabilities & Shareholder's Equity 1,057 547 595 639 454
Total Common Equity 874 356 371 416 220
Shares Outstanding 42.70 42.70 30.00 30.00 30.00
Book Value Per Share 20.46 8.34 12.36 13.87 7.34